Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Reduce” by Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been assigned a consensus rating of “Reduce” from the seven research firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $35.60.

STRO has been the topic of a number of research reports. Wall Street Zen lowered Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Wedbush restated a “neutral” rating and set a $100.00 price objective (up previously from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sutro Biopharma in a report on Monday, December 1st.

Sutro Biopharma Stock Up 0.2%

NASDAQ STRO opened at $9.83 on Monday. The company has a market capitalization of $83.65 million, a price-to-earnings ratio of -0.38 and a beta of 1.62. Sutro Biopharma has a twelve month low of $5.23 and a twelve month high of $22.30. The stock has a fifty day simple moving average of $9.28 and a 200 day simple moving average of $8.75.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.25). The company had revenue of $9.69 million during the quarter, compared to analyst estimates of $10.14 million. Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 206.77%. Research analysts expect that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Connie Matsui bought 5,000 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $40,000.00. Following the completion of the purchase, the director directly owned 5,000 shares in the company, valued at $40,000. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have bought a total of 11,175 shares of company stock valued at $89,598 over the last 90 days. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Sutro Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of STRO. Jacobs Levy Equity Management Inc. bought a new stake in shares of Sutro Biopharma in the third quarter valued at $387,000. Velan Capital Investment Management LP increased its holdings in Sutro Biopharma by 2.0% in the 3rd quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after acquiring an additional 60,000 shares during the last quarter. Bank of America Corp DE raised its stake in Sutro Biopharma by 51.3% in the 3rd quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock valued at $104,000 after acquiring an additional 40,488 shares during the period. Shay Capital LLC lifted its holdings in Sutro Biopharma by 20.1% during the third quarter. Shay Capital LLC now owns 312,051 shares of the company’s stock valued at $271,000 after purchasing an additional 52,162 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in Sutro Biopharma by 244.8% during the third quarter. Two Sigma Investments LP now owns 396,785 shares of the company’s stock worth $345,000 after purchasing an additional 281,717 shares during the period. 96.99% of the stock is owned by institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.